Qiumin Luo

689 total citations
22 papers, 404 citations indexed

About

Qiumin Luo is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Qiumin Luo has authored 22 papers receiving a total of 404 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hepatology, 14 papers in Epidemiology and 5 papers in Infectious Diseases. Recurrent topics in Qiumin Luo's work include Liver Disease Diagnosis and Treatment (11 papers), Liver Disease and Transplantation (9 papers) and Hepatitis C virus research (8 papers). Qiumin Luo is often cited by papers focused on Liver Disease Diagnosis and Treatment (11 papers), Liver Disease and Transplantation (9 papers) and Hepatitis C virus research (8 papers). Qiumin Luo collaborates with scholars based in China. Qiumin Luo's co-authors include Wenxiong Xu, Liang Peng, Zhiliang Gao, Xuejun Li, Dabiao Chen, Zhanlian Huang, Ziying Lei, Jing Liu, Bingliang Lin and Yeqiong Zhang and has published in prestigious journals such as Frontiers in Microbiology, Medicine and BioMed Research International.

In The Last Decade

Qiumin Luo

20 papers receiving 399 citations

Peers

Qiumin Luo
Mark J. Hobeika United States
Jipin Jiang China
Simona De Michele United States
YU Jin-hong China
Erik L. Lum United States
Jun Xiong China
Hanaa Nafady‐Hego Egypt
Harsh Vardhan Tevethia India
Nauman Siddiqi Saudi Arabia
Arnaud Devresse Belgium
Mark J. Hobeika United States
Qiumin Luo
Citations per year, relative to Qiumin Luo Qiumin Luo (= 1×) peers Mark J. Hobeika

Countries citing papers authored by Qiumin Luo

Since Specialization
Citations

This map shows the geographic impact of Qiumin Luo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qiumin Luo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qiumin Luo more than expected).

Fields of papers citing papers by Qiumin Luo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Qiumin Luo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qiumin Luo. The network helps show where Qiumin Luo may publish in the future.

Co-authorship network of co-authors of Qiumin Luo

This figure shows the co-authorship network connecting the top 25 collaborators of Qiumin Luo. A scholar is included among the top collaborators of Qiumin Luo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Qiumin Luo. Qiumin Luo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chen, Xiyao, Xin Song, Lina Wu, et al.. (2025). Nucleolar NOL9 regulated by DNA methylation promotes hepatocellular carcinoma growth through activation of Wnt/β-catenin signaling pathway. Cell Death and Disease. 16(1). 100–100. 5 indexed citations
2.
Chen, Jia, Wenxiong Xu, Xiyao Chen, et al.. (2024). Baicalein upregulates macrophage TREM2 expression via TrKB-CREB1 pathway to attenuate acute inflammatory injury in acute-on-chronic liver failure. International Immunopharmacology. 139. 112685–112685. 6 indexed citations
3.
Xu, Wenxiong, Qiumin Luo, Yeqiong Zhang, Chan Xie, & Liang Peng. (2024). A case report: cccDNA and pgRNA remain positive in liver tissue in a chronic hepatitis B patient with functional cure. Frontiers in Medicine. 11. 1427043–1427043. 1 indexed citations
4.
5.
6.
Song, Xin, Xiyao Chen, Qiumin Luo, et al.. (2024). Evaluating the impact of treatment sequencing on outcomes in hepatocellular carcinoma: a comparative analysis of TACE and systemic therapies. Clinical and Experimental Medicine. 24(1). 238–238. 1 indexed citations
7.
Luo, Qiumin, Jia Chen, Yeqiong Zhang, et al.. (2024). Viral hepatitis E: Clinical manifestations, treatment, and prevention. Liver Research. 8(1). 11–21. 6 indexed citations
8.
Wang, Lu, Wenxiong Xu, Shu Zhu, et al.. (2023). Double Plasma Molecular Adsorption System with Sequential Low-dose Plasma Exchange in Patients with Hepatitis B Virus-related Acute-on-chronic Liver Failure: A Prospective Study. Journal of Clinical and Translational Hepatology. 0(0). 0–0. 5 indexed citations
9.
Xu, Wenxiong, Yanlin Huang, Yongyu Mei, et al.. (2022). High Expression of POGK Predicts Poor Prognosis in Patients with Hepatocellular Carcinoma. Current Oncology. 29(11). 8650–8667. 4 indexed citations
10.
Wang, Lu, Ying Liu, Wenxiong Xu, et al.. (2022). Prognostic value of decline in model for end-stage liver disease score and hepatic encephalopathy in hepatitis B-related acute-on-chronic liver failure patients treated with plasma exchange. Scandinavian Journal of Gastroenterology. 57(9). 1089–1096. 2 indexed citations
11.
12.
Wang, Lu, Wenxiong Xu, Xuejun Li, et al.. (2022). Long-term prognosis of patients with hepatitis B virus–related acute-on-chronic liver failure: a retrospective study. BMC Gastroenterology. 22(1). 162–162. 7 indexed citations
13.
Luo, Qiumin, et al.. (2022). [Research advances in the treatment of liver failure with mesenchymal stem cell-derived exosomes].. PubMed. 30(3). 249–252. 1 indexed citations
14.
Zhang, Yeqiong, Zhipeng Li, Qiumin Luo, et al.. (2022). Changes in blood lipids in patients with chronic hepatitis B after 48 weeks of tenofovir alafenamide treatment: A prospective real-world clinical study. Antiviral Therapy. 27(2). 7 indexed citations
15.
Peng, Liang, Jing Liu, Wenxiong Xu, et al.. (2020). SARS‐CoV‐2 can be detected in urine, blood, anal swabs, and oropharyngeal swabs specimens. Journal of Medical Virology. 92(9). 1676–1680. 301 indexed citations
16.
Yang, Xiaohua, Yongyu Mei, Guoli Lin, et al.. (2019). Barriers to hepatitis C virus treatment in Guangdong Province. Annals of Palliative Medicine. 8(5). 640–644. 2 indexed citations
17.
18.
Li, Zhanyi, Ying Liu, Ying Zhang, et al.. (2017). Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients. BioMed Research International. 2017. 1–8. 15 indexed citations
19.
Luo, Qiumin, Qingxian Cai, Fulong Zhang, et al.. (2016). An outbreak of HCV genotype 6a and 2a infection in South China: Confirmation of iatrogenic transmission by phylogenetic analysis of the NS5B region. Molecular Medicine Reports. 14(5). 4285–4292. 3 indexed citations
20.
Cai, Qingxian, et al.. (2014). Effect of Drug Resistance Mutations on Antiviral Agents in HCV Patients. Antiviral Therapy. 21(5). 369–375. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mark J. Hobeika Breakdown of academic impact, for papers by Jipin Jiang Breakdown of academic impact, for papers by Simona De Michele Breakdown of academic impact, for papers by YU Jin-hong Breakdown of academic impact, for papers by Erik L. Lum Breakdown of academic impact, for papers by Jun Xiong Breakdown of academic impact, for papers by Hanaa Nafady‐Hego Breakdown of academic impact, for papers by Harsh Vardhan Tevethia Breakdown of academic impact, for papers by Nauman Siddiqi Breakdown of academic impact, for papers by Arnaud Devresse
Rankless by CCL
2026